| CEO Name | Daniel O'Day |
| Nationality | United States |
| Net Worth Estimation | $80 million |
Daniel O'Day's estimated net worth of around $80 million primarily derives from his executive compensation, stock awards, and performance bonuses as CEO of Gilead Sciences, as well as his prior leadership roles at Roche. Public SEC filings and disclosures report significant equity holdings and annual compensation packages contributing to this valuation.
Daniel O'Day, CEO of Gilead Sciences, has an estimated net worth of $80,000,000, which is 100% of the maximum and 800% of the minimum net worth benchmark for biotechnology CEOs. His net worth places him at the top end of the estimated range for CEOs in this business category.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Daniel O'Day Performance in Gilead Sciences
Daniel O'Day, CEO of Gilead Sciences, demonstrates decisive leadership by strategically focusing on innovation in antiviral therapies and expanding the company's oncology portfolio. His decision-making emphasizes sustainable growth through disciplined investment and operational efficiency, driving robust financial performance. Under O'Day's leadership, Gilead has strengthened its market position, enhanced pipeline productivity, and accelerated advancement of critical therapies, significantly impacting the company's long-term value.
Latest News
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo(r) (Lenacapavir).
Gilead's innovative HIV prevention drug Yeztugo (lenacapavir), a first-in-class, twice-yearly injectable, was recognized for its scientific advancement and public health impact, marking a significant milestone in HIV prevention--CEO Daniel O'Day emphasized the collaborative effort behind the breakthrough. The company continues to expand access, recently announcing a no-profit deal with the Global Fund to provide this treatment in low-income countries while maintaining strong financial growth and leadership in HIV innovation.
Source: http://www.gilead.com/news/news-details/2025/gilead-sciences-wins-prestigious-2025-prix-galien-usa-award-for-best-pharmaceutical-product-with-yeztugo-lenacapavir